期刊文献+

福辛普利钠在大鼠肠道的吸收性质

Absorption properties of fosinopril sodium in rat intestine
原文传递
导出
摘要 目的:建立大鼠肠灌流液中福辛普利钠的HPLC测定方法,研究福辛普利钠在大鼠小肠的吸收性质。方法:采用HPLC法测定肠灌流液中福辛普利钠的浓度,考察大鼠小肠单向灌流试验中不同肠段、灌流液pH值和二肽甘氨酰肌氨酸(Gly-Sar)浓度对药物肠道渗透性的影响。结果:HPLC方法的专属性和重现性均符合生物样品测定要求,内源性物质不干扰测定。福辛普利钠在大鼠不同肠段的有效渗透系数大小依次为十二指肠>空肠>回肠;药物在三肠段的吸收随着灌流液pH值的降低呈增加趋势;此外,低浓度Gly-Sar可促进福辛普利钠的小肠吸收,但浓度较高时则有一定抑制作用。结论:本文建立的HPLC方法简便、灵敏、精密度好,可用于福辛普利钠肠道吸收的研究;影响Pept1活性的因素可改变福辛普利钠的肠道吸收。 OBJECTIVE To establish an HPLC method for determining concentrations of fosinopril sodium in the rat intesti nal perfusate and study the absorption of fosinopril sodium in rat intestine. METHODS HPLC was used to determine the con- centration of fosinopril sodium. In situ single-pass intestinal perfusion was employed to investigate the effects of different intes tine segments,different pH of perfusate and different concentrations of Gly-Sar on the permeability of fosinopril sodium in rat intestine. RESULTS An HPLC method was developed and endogenous substances did not interfere with the assay. Fosinopril sodium was mainly absorbed in the upper small intestine (duodenum and jejunum), and the lower pH of perfusate enhanced the intestinal absorption of fosinopril sodium in different segments of rat intestine. The lower concentration Gly Sar could increase the absorption of fosinopril sodium,however the high concentration reduced the absorption. CONCLUSION The HPLC method used in the present study is simple, sensitive,accurate and can be used to study the absorption of fosinopril sodium in rat intes- tine. The factors which affected the active of Peptl could change the intestinal absorption of fosinopril sodium.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2013年第11期840-844,共5页 Chinese Journal of Hospital Pharmacy
基金 国家自然科学基金资助项目(编号:30901860)
关键词 高效液相色谱法 福辛普利钠 大鼠单向灌流 寡肽转运载体 甘氨酰肌氨酸 HPLC fosinopril sodium single-pass perfusion Peptl Gly Sar
  • 相关文献

参考文献2

二级参考文献41

  • 1饶中和,袁志敏.第三代ACE抑制剂福辛普利及其降压作用[J].心血管病学进展,1995,16(6):351-354. 被引量:9
  • 2[1]Dunn CJ,Peters DH.Metformin.A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.Drugs 1995; 49:721-749
  • 3[2]Tucker GT,Casey C,Phillips PJ,Connor H,Ward JD,Woods HF.Metformin kinetics in healthy subjects and in patients with diabetes mellitus.Br J Clin Pharmacol1981; 12:235-246
  • 4[3]Vidon N,Chaussade S,Noel M,Franchisseur C,Huchet B,Bernier JJ.Metformin in the digestive tract.Diabetes Res Clin Pract 1988; 4:223-229
  • 5[4]Fojo AT,Ueda K,Slamon DJ,Poplack DG,Gottesman MM,Pastan I.Expression of a multidrug-resistance gene in human tumors and tissues.Proc Natl Acad Sci USA 1987; 84:265-269
  • 6[5]Thiebaut F,Tsuruo T,Hamada H,Gottesman MM,Pastan I,Willingham MC.Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proc Natl Acad Sci USA 1987; 84:7735-7738
  • 7[6]Terao T,Hisanaga E,Sai Y,Tamai I,Tsuji A.Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier.J Pharm Pharmacol1996; 48:1083-1089
  • 8[7]Greiner B,Eichelbaum M,Fritz P,Kreichgauer HP,yon Richter O,Zundler J,Kroemer HK.The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.J Clin Invest 1999; 104:147-153
  • 9[8]Ambudkar SV,Dey S,Hrycyna CA,Ramachandra M,Pastan I,Gottesman MM.Biochemical,cellular,and pharmacological aspects of the multidrug transporter.Annu Rev Pharmacol Toxicol 1999; 39:361-398
  • 10[9]Williams GC,Sinko PJ.Oral absorption of the HIV protease inhibitors:a current update.Adv Drug Deliv Rev 1999; 39:211-238

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部